In the pentose phosphate pathway (PPP), mild FSHD patients exhibited increased levels of hexose-6-phosphate dehydrogenase (H6PD), a significant source of reducing power and metabolic intermediates that can be used as an alternative to glycolysis. The gene discussed is H6PD; the disease is facioscapulohumeral muscular dystrophy.